Oppenheimer reissued their outperform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report released on Saturday morning, MarketBeat.Com reports. The brokerage currently has a $124.00 price target on the biopharmaceutical company’s stock.

Gilead Sciences (NASDAQ:GILD) traded down 5.18% during mid-day trading on Friday, reaching $83.00. 37,029,026 shares of the company’s stock were exchanged. The stock has a market cap of $119.62 billion and a P/E ratio of 7.62. The stock has a 50-day moving average price of $96.84 and a 200-day moving average price of $105.15. Gilead Sciences has a 52 week low of $82.33 and a 52 week high of $123.37.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $3.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.87 by $0.35. The business earned $8.30 billion during the quarter, compared to analyst estimates of $7.84 billion. The business’s quarterly revenue was up 37.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 earnings per share. On average, analysts forecast that Gilead Sciences will post $12.21 earnings per share for the current year.

A number of other analysts have also weighed in on GILD. Needham & Company LLC restated a buy rating and issued a $125.00 target price on shares of Gilead Sciences in a research note on Wednesday. JPMorgan Chase & Co. restated an overweight rating and issued a $133.00 target price on shares of Gilead Sciences in a research note on Wednesday, January 13th. Piper Jaffray restated a buy rating and issued a $134.00 target price on shares of Gilead Sciences in a research note on Saturday, January 9th. Vetr upgraded Gilead Sciences from a buy rating to a strong-buy rating and set a $119.36 target price for the company in a research note on Friday, November 13th. Finally, Maxim Group restated a buy rating and issued a $137.00 target price (up from $129.00) on shares of Gilead Sciences in a research note on Wednesday, October 28th. Eight equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $125.10.

In related news, CFO Robin L. Washington sold 6,250 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $109.46, for a total transaction of $684,125.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John C. Martin sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $109.42, for a total value of $16,413,000.00. Following the transaction, the chief executive officer now directly owns 3,948,066 shares in the company, valued at $431,997,381.72. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have bought and sold shares of the company. PGGM Investments acquired a new position in Gilead Sciences during the fourth quarter worth $97,203,000. Verde Servico Internacionais purchased a new stake in Gilead Sciences during the fourth quarter valued at about $59,733,000. Boston Advisors increased its stake in Gilead Sciences by 149.7% in the fourth quarter. Boston Advisors now owns 649,349 shares of the biopharmaceutical company’s stock valued at $65,708,000 after buying an additional 389,321 shares during the period. Nationwide Fund Advisors increased its stake in Gilead Sciences by 18.9% in the fourth quarter. Nationwide Fund Advisors now owns 1,609,518 shares of the biopharmaceutical company’s stock valued at $162,867,000 after buying an additional 255,845 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in Gilead Sciences by 23.9% in the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 624,402 shares of the biopharmaceutical company’s stock valued at $63,184,000 after buying an additional 120,419 shares during the period.

Gilead Sciences, Inc. (NASDAQ:GILD), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

12 Month Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.